← Back to patent-cliff list
CAS 108-89-4
4-methylpyridine
Codes: TOFA-029, TIRO-021
Application context (from source-drug indications)
Ankylosing spondylitisTofacitinib CitrateJuvenile rheumatoid arthritisTofacitinib CitrateUlcerative colitisTofacitinib CitratePsoriatic arthritisTofacitinib CitrateRheumatoid arthritisTofacitinib CitrateUnstable anginaTirofiban Hydrochloride HydrateMyocardial infarctionTirofiban Hydrochloride HydrateCoronary thrombosisTirofiban Hydrochloride HydrateAcute coronary syndromeTirofiban Hydrochloride HydrateThrombosisTirofiban Hydrochloride HydrateCerebral infarctionTirofiban Hydrochloride Hydrate
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Tofacitinib Citrate | Tier B — Position early | 2028 |
| Tirofiban Hydrochloride Hydrate | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
N-(1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine→N-methyl-N-(4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine→2-cyanoacetyl chloride→4-methylpyridine→1-benzyl-4-methyl-1,2,3,6-tetrahydropyridine→(3S,4R)-1-benzyl-4-methylpiperidin-3-ol→N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
(S)-2-amino-3-(4-hydroxyphenyl)propanoic acid→butane-1-sulfonyl chloride hydrochloride→(S)-2-(butylsulfonamido)-3-(4-hydroxyphenyl)propanoic acid→TIRO-018→(S)-2-(butylsulfonamido)-3-(4-(4-(pyridin-4-yl)butoxy)phenyl)propanoic acid→(S)-2-(butylsulfonamido)-3-(4-(4-(piperidin-4-yl)butoxy)phenyl)propanoic acid→4-methylpyridine→1-bromo-3-chloropropane
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Unibest Nantong cGMP Site | （3R,4R)-N,4-Dimethyl-1-(phenylmethyl)-3-piperidinamine HCL Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 4-Chloro-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidine Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 1-benzyl-4-methylpiperidin-3-one Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.